Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Feb 21, 2017 9:36pm
203 Views
Post# 25875087

RE:RE:RE:Jd..this is directly to you...kayacker i have no issue with

RE:RE:RE:Jd..this is directly to you...kayacker i have no issue withlol..you are right about that kayaker lol...he did predict this to be worth a pilr of money by now too lol....so i guess if you can laugh at dr jekyls predictions that you can certainly laugh at jds 18$ predictions as well...since we obviously see that that has mot happened right kayaker??? I Mean you have to be fair here right?....

Wrong again Oilpatch. Jekyl likes to pretend (in his usual arrogant style) that he's had it figured out all along. His posting record says something else.  So if he dupes you into posting that he was right, it begs for a correction.

On the other hand, JD has been upfront, candid, straightforward, and otherwise forthright about his predictions.  He doesn't try to pretend he said something else.

Got it?

PS.  You get bonus points for finally spelling "kayaker" without a "c".



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities